Led · Series A · Jun 2026

Oak Hill Bio focuses on acquiring and developing rare disease therapeutics that were deprioritized by larger pharmaceutical companies. Its lead program, rugonersen (OHB-724), is an antisense oligonucleotide designed to unsilence the paternal UBE3A allele and has demonstrated promising preclinical and Phase 1 data. Rugonersen was originally developed at Roche and is expected to enter a Phase 3 study in mid-2026. Several former members of the rugonersen program have joined Oak Hill Bio to lead its development. The company was formed in 2024 as a subsidiary of Oak Hill Bio Holdings and is based in Cambridge, Mass. Oak Hill Bio Holdings is also developing OHB-607, a replacement therapy currently in a Phase 2b study.

Participated · Equity · Mar 2026

Candid Therapeutics is advancing a pipeline of bispecific T-cell engager (TCE) antibodies that selectively direct T cells to eliminate disease-causing B cells and plasma cells in autoimmune disorders. Its lead candidate, cizutamig, targets BCMA and CD3 and has been administered to 87 patients (47 with autoimmune diseases), showing favorable tolerability with only mild cytokine release syndrome; Phase 2 studies in myasthenia gravis and rheumatologic interstitial lung disease are slated for 2026. Additional assets include CND261, a CD20-directed TCE already tested in over 100 patients, and CND319, a dual CD19/CD20 engager expected to enter first-in-human trials in mid-2026, plus a preclinical BCMA/CD19 program. The company is led by Chairman, President and CEO Dr. Ken Song and, following a planned merger with Rallybio, will trade on Nasdaq under the ticker CDRX. An oversubscribed private financing of more than $505 million, together with Rallybio’s cash, will leave the combined entity with roughly $700 million at closing, providing funding runway through 2030. These resources are earmarked to advance multiple clinical milestones, including the Phase 2 trials for cizutamig and early-stage studies for next-generation TCEs.

Participated · Series F · Jan 2026

Parabilis Medicines is pioneering stabilized, cell-penetrant α-helical peptides, called Helicons™, to modulate intracellular proteins that small molecules and antibodies cannot reach. Its lead candidate, FOG-001 (zolucatetide), directly inhibits the β-catenin:TCF interaction within the Wnt/β-catenin pathway and has shown meaningful single-agent activity across five tumor types, including desmoid tumors and adamantinomatous craniopharyngioma. The drug has U.S. FDA Fast Track Designation for desmoid tumors and is moving toward a registrational trial while additional data in hepatocellular carcinoma and familial adenomatous polyposis are forthcoming. Beyond FOG-001, Parabilis is advancing preclinical Helicon degraders against ERG and allosteric ARON for prostate cancer, demonstrating the broad applicability of its platform. Headquartered in Cambridge, Massachusetts, the company leverages proprietary data, AI- and physics-based algorithms, and more than a decade of laboratory innovation. Financially, Parabilis closed an oversubscribed $305 million Series F round at an increased valuation, positioning it to expand clinical and preclinical programs. No revenue or user metrics have been disclosed, consistent with its clinical-stage status.

Participated · Series B · Dec 2025

Aeovian Pharmaceuticals is focused on restoring cellular metabolic quality control through highly selective inhibition of mTORC1 or CD38. Its lead candidate, AV078, is a first-in-class, CNS-penetrant selective mTORC1 inhibitor engineered to bypass the toxicities seen with non-selective mTOR blockers such as everolimus. Following encouraging Phase 1 data, AV078 is being advanced into a Phase 2 proof-of-concept trial for patients with TSC-related refractory epilepsy, a condition that affects roughly one million people worldwide and remains resistant to therapy in about two-thirds of cases. The company’s wholly owned pipeline aims to expand selective mTORC1 inhibition to additional rare and age-related indications. Proceeds from its recent financing will support the Phase 2 study and further pipeline development. Aeovian operates out of Berkeley, California and remains privately held; no revenue or user metrics were disclosed in the article.

Participated · Series C · Apr 2025

Attovia leverages its ATTOBODY platform, which uses spatial positioning technology to achieve biparatopic target engagement, to develop multi-specific biologics for immune-mediated diseases. Its lead candidate, ATTO-1310, is a half-life extended anti‑IL31 biologic currently in Phase 1 for chronic pruritus of unknown origin and other pruritic conditions. The company is advancing ATTO-3712, a half-life extended anti‑IL13 x IL31 bispecific, and plans to start Phase 1 studies for ATTO-3712 in the second half of 2025. Earlier-stage programs include ATTO-004, a multi-specific candidate targeting IBD, plus two discovery-stage multi-specific programs. Attovia was founded by CEO Tao Fu and is positioned to use new capital to advance its clinical and discovery-stage pipeline. The company announced board expansion alongside its financing. Attovia is developing a pipeline of biotherapeutics with an initial focus on immune-mediated diseases and uses the ATTOBODY™ biparatopic biologics platform. The platform is designed to generate binders that offer stronger efficacy and access a broader universe of druggable epitopes compared to traditional approaches. Its lead programs are ATTO-1310, a potential first-in-class, long half-life anti-IL31 ATTOBODY, and ATTO-002, a bispecific anti-IL31 x IL13 ATTOBODY targeting atopic dermatitis and other pruritic diseases. ATTO-1310 is in IND-enabling studies and is on track to enter the clinic around year-end 2024; Attovia expects to nominate a development candidate for ATTO-002 in the second half of 2024 and advance the candidate to IND in 2025. The company raised $105M in Series B financing, bringing total funding to $165M, and plans to use proceeds to advance lead programs to initial clinical data readouts, expand its immunology and inflammation pipeline, and further develop the ATTOBODY platform. Led by CEO Tao Fu, Attovia is also developing discovery-stage programs to expand the ATTOBODY footprint to novel, difficult-to-drug targets and multi-specific combinations. Attovia Therapeutics is a California-based company developing a pipeline of biotherapeutics for immune-mediated disease and oncology built on the Attobody™ biparatopic nanobody platform. The platform produces small-format binders with low picomolar affinity, enhanced specificity, accelerated internalization and fast tissue penetration. Attovia’s lead program is an Attobody to treat immune disease; the company is progressing multiple programs and plans to initiate additional discovery projects. The company will use proceeds to achieve clinical proof-of-concept on its lead program, nominate additional development candidates across immunology and oncology, and continue to advance the Attobody technology. Attovia was launched by Alamar Biosciences and Frazier Life Sciences and will receive an exclusive worldwide license to the Attobody platform and associated IP and pipeline assets in exchange for equity and potential milestones and royalties. Tao Fu will serve as CEO; the leadership team includes CSO Petter Veiby, CTO Hangjun Zhan, and CBO Zaneta Odrowaz.